Top Analysts Identify 3 Biotech Stocks with Strong Buy Potential
Wall Street's top analysts have spotlighted three biotech stocks demonstrating significant upside potential, with price targets suggesting aggressive growth trajectories. PASG leads the pack with a 400% implied upside, backed by unanimous Buy ratings from covering analysts. The clinical-stage firm specializes in gene therapies for rare brain disorders.
BNTX follows closely, leveraging its mRNA technology platform for vaccine development. Despite mixed analyst coverage, the company maintains a robust price target of $151 per share. Market observers note the sector's momentum reflects broader institutional interest in breakthrough medical technologies.